NCT04205227 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04205227
Title	ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors
Recruitment	Active, not recruiting
Gender	both
Phase	Phase Ib/II
Variant Requirements	No
Sponsors	ENB Therapeutics, Inc
Indications	peritoneal carcinoma sarcoma endometrioid ovary carcinoma mesenchymal chondrosarcoma leiomyosarcoma synovial sarcoma pancreatic adenocarcinoma fallopian tube carcinoma chondrosarcoma Advanced Solid Tumor Ewing sarcoma liposarcoma ovarian clear cell carcinoma pancreatic intraductal papillary-mucinous neoplasm melanoma ovarian serous carcinoma dedifferentiated liposarcoma malignant fibrous histiocytoma osteosarcoma
Therapies	ENB003 + Pembrolizumab
Age Groups:	adult \| senior
Covered Countries	USA \| AUS

Facility	City	State	Zip	Country	Details
Cedars Sinai-The Angeles Clinic	Los Angeles	California	90025	United States	Details
MD Anderson Cancer Center	Houston	Texas	77030	United States	Details
Border Medical Oncology	Albury	New South Wales	2640	Australia	Details
Blacktown Oncology	Blacktown	New South Wales	2148	Australia	Details
Kinghorn-St Vincent's Hospital	Darlinghurst	New South Wales	2010	Australia	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT04205227Clinical Trial Detail